SuperworthFate Therapeutics shares outstanding FATE
Diluted shares outstanding, averaged over each quarter, from 2012.
- Latest quarter, to Jun 30, 2026
- 120.4M
- On a year earlier
- +1.6%
- more shares
Fate Therapeutics had 120.4M diluted shares outstanding on average in Q2 FY26, the quarter to Jun 30, 2026.
That is 1.6% more than a year earlier, so each share owns a little less of the company.
Shares outstanding over time
Fiscal year by fiscal year
| Fiscal year | Shares, fourth quarter | Change |
|---|---|---|
| FY2025 | 119.2M | +1% |
| FY2024 | 117.8M | +19% |
| FY2023 | 98.6M | +1% |
| FY2022 | 97.2M | +1% |
| FY2021 | 95.8M | +10% |
| FY2020 | 87.4M | +16% |
| FY2019 | 75.6M | +17% |
| FY2018 | 64.6M | +48% |
| FY2017 | 43.7M | +17% |
| FY2016 | 37.2M | +30% |
| FY2015 | 28.7M | +40% |
| FY2014 | 20.5M | +1633% |
| FY2012 | 1.2M | n/a |
Each fiscal year is the twelve months to its fourth quarter, shown as the fourth quarter's average share count.
Quarter by quarter
| Quarter | Ended | Shares outstanding | On a year earlier |
|---|---|---|---|
| Q2 FY26 | 120.4M | +2% | |
| Q1 FY26 | 120M | +1% | |
| Q4 FY25 | 119.2M | +1% | |
| Q3 FY25 | 119M | +1% | |
| Q2 FY25 | 118.5M | +1% | |
| Q1 FY25 | 118.4M | +17% | |
| Q4 FY24 | 117.8M | +19% | |
| Q3 FY24 | 117.8M | +19% | |
| Q2 FY24 | 117.5M | +19% | |
| Q1 FY24 | 101.1M | +3% | |
| Q4 FY23 | 98.6M | +1% | |
| Q3 FY23 | 98.6M | +2% |
What the shares outstanding tells you
Diluted shares outstanding, averaged over the period. Fewer shares means each one owns more of the company.
A falling count usually means buybacks. A rising one means stock pay, acquisitions paid in shares or new shares sold.
More on Fate Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.